key: cord-0313829-fagcyea9
authors: Anderson, Enyia R; Patterson, Edward I; Richards, Siobhan; Green, Alison; Mukherjee, Sayandip; Hoptroff, Michael; Hughes, Grant L
title: Virucidal activity of CPC-containing oral rinses against SARS-CoV-2 variants and are active in the presence of human saliva
date: 2021-09-22
journal: bioRxiv
DOI: 10.1101/2021.08.05.455040
sha: 6f9bc6919c32bc902561b0eb2d572daee9aeda6d
doc_id: 313829
cord_uid: fagcyea9

The role of human saliva in aerosol-based transmission of SARS-CoV-2 has highlighted the need to understand the potential of oral hygiene products to inactivate the virus. Here we examined the efficacy of mouthwashes containing cetylpyridinium chloride (CPC) or chlorhexidine (CHX) in inactivating SARS-CoV-2. After 30 seconds contact under standard aqueous conditions CPC mouthwashes achieved a ≥4.0log10 PFU/mL reduction in SARS-CoV-2 (USA-WA1/2020) titres whereas comparable products containing CHX achieved <2.0log10 PFU/mL reduction. Further testing with CPC mouthwashes demonstrated efficacy against multiple SARS-CoV-2 variants, with inactivation below the limit of detection observed against the Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) variants. Virucidal efficacy of CPC mouthwash was also observed in the presence of human saliva with the product delivering ≥4.0log10 PFU/mL reduction in SARS-CoV-2 titres after 30 seconds providing additional evidence for the virucidal efficacy of CPC mouthwashes under simulated physiological conditions. Together these data suggest CPC-based mouthwashes are effective at inactivating SARS-CoV-2 and further supports the use of mouthwash to mitigate the risk of transmission during dentistry procedures.

The high viral load of SARS-CoV-2 present in the saliva of infected individuals and their ease of 38 aerosolisation means that saliva is recognised as playing a key role in the transmission of SARS-CoV-2 39 [1] [2] [3] . The potential of the oral cavity to act as a viral reservoir is supported by the presence of the 40 angiotensin-converting enzyme 2 (ACE-2) receptor in oral gingival epithelia and salivary glands and 41 the infection of these tissues by SARS-CoV-2 in vivo [4] , potentially aggravating systemic infection via 42 an oral-vasculo-pulmonary route [5] . 43

The use of oral rinses or mouthwashes have been proposed by health organisations to mitigate 44 transmission of SARS-CoV-2 during dentistry procedures due to their demonstrated efficacy in 45 deactivating SARS-CoV-2 in vitro and in vivo [6] [7] [8] . The antimicrobial action of a mouthwash is 46 dependent on a combination of the active ingredients, their intrinsic efficacy, and their bioavailability 47 during use. Active ingredients used in mouthwashes include Quaternary Ammonium Compounds 48 (QACS) such as Dequalinium chloride, benzalkonium chloride, cetyl pyridinium chloride (CPC) and 49 chlorhexidine (CHX) which are believed function as antimicrobials via a stepwise process of charge 50 mediated attraction and destabilisation of the lipid envelop [9] [10] [11] . 51 CPC is widely used in mouthwash formulations displaying substantive action against a range of oral 52 bacteria [12] [13] [14] and viruses, including [15] [16] [17] , whilst data on antiviral efficacy of CHX 53 against SARS-CoV-2 has been more varied [18] [19] [20] [21] [22] . All mouthwashes, regardless of composition, must 54 function in situ in the oral cavity, and hence must retain efficacy in the presence of human saliva, 55 overcoming any potential deactivation from salivary components [23] [24] [25] . 56

To investigate the impact of formulation composition on efficacy we compared the in vitro virucidal 57 efficacy of mouthwashes containing 0.07% CPC and 0.2% CHX digluconate against a range of SARS-58

CoV-2 variants. In addition, the efficacy of a representative CPC containing mouthwash was also 59 investigated in the presence of human saliva. Our findings suggest CPC mouthwashes offer potent 60 virucidal activity that is effective against all variants tested and which is maintained in the presence of 61 formula was added to 100 µL of human saliva mixed with 100 µL of SARS-CoV-2 (USA-WA1/2020) 97

inoculum. The solution was incubated for 30 seconds and 9 mL of DE broth added. As a control, 800 98 µL of MW-B mouthwash formula was added to 100 µL of sterile water and 100 µL of virus inoculum, 99 with 9 mL of DE broth added after 30 seconds of incubation. Experiments were carried out in duplicate. 100 101 Saliva, neutralisation, and cytotoxicity assays 102 To assess if human saliva has inherent antiviral action against SARS-CoV-2 (USA-WA1/2020), 100 µL 103 of virus inoculum was added to either 800 µL of sterile water and 100 µL of irradiated human saliva 104 (dilute saliva), or 900µL of irradiated human saliva (neat saliva) for a 5-minute incubation. After 5 105 minutes had elapsed, a 25 µL sample was placed into a dilution series. Neutralisation controls were 106 carried out by adding 9 mL of DE broth to 900 µL of mouthwash formula. To this, 100 µL of virus 107 suspension was added for 30 seconds and 25 µL removed to a dilution series and a standard plaque 108 assay preformed. To determine the cytotoxicity of the mouthwashes, 100 µL of 4% DMEM was 109 added to 900 µL of test mouthwash formula for 30 seconds. To this 9 mL of DE broth was added and 110 25 µL placed into dilution series for a standard plaque assay. 25 µL samples from each condition 111 were serial diluted 10-fold to be quantified through a standard plaque assay. Plaques were counted 112 to determine viral titre. All experiments were carried out in triplicate. 113

Comparison of CPC and CHX containing mouthwashes 116 We tested the ability of CPC and CHX to inactivate SARS-CoV-2 (USA-WA1/2020). Following a 30 117 second incubation in the presence of the test mouthwashes a reduction in viral titre of ≥4.0log10 118 PFU/mL was observed with MW-A and MW-B and of <2.0 log10 PFU/mL for MW-C. No reduction of 119 viral titre occurred in the water control and however complete inactivation was observed by the 70% 120 ethanol control. All treatments were effectively neutralised by the addition of DE broth (Figure 2 ). 121

Cytotoxicity assays were able to determine the limit of detection (LOD) for this assay. The LOD is the 122 point at which Vero E6 cell death is due to cytotoxicity of mouthwashes rather than SARS-CoV-2. For 123 all three mouthwashes presented here, cytopathic effect was observed at 2.0log10 PFU/mL. were incubated with SARS-CoV-2 inoculum for 30 seconds. Both MW-A and MW-B reduced to below 129 the limit of detection (LOD), while MW-C reduced viral titre by 1.26log10 PFU/mL compared to the 130 water control. LOD = 2.0log10 PFU/mL. Viral titres recovered from the water control averaged 131 6.12log10 PFU/mL, while viral titre recovered from neutralisation controls were within 1. Inactivation of SARS-CoV-2 Variants by Test Products

We also tested the ability of CPC and CHX to inactivate SARS-CoV-2 variants of concern, Alpha, Beta 139 and Gamma. Following the 30 second incubation of Alpha with MW-A and MW-B an average reduction 140 of 3.11log10 PFU/mL to below the LOD was seen. Incubation of Beta with test products saw an average 141 reduction of 4.1log10 PFU/mL, whilst Gamma saw an average reduction of 3.36log10 PFU/mL, both to 142 below the LOD (Table 1 ). In assays carried out with the variants, no reduction was seen in the water 143 control and reduction below the LOD was seen in the 70% ethanol control. The ability to achieve a 144 4.0log10 PFU/mL in the variant assays was dependent on titres of SARS-CoV-2 variants following 145 standard propagation methods. 146 investigations were undertaken to assess whether saliva displays any measurable endogenous 155 antiviral activity against SARS-CoV-2 (USA-WA1/2020) or whether it acts as an inhibitory "soil" 156 quenching the antiviral function of mouthwash formulations. The endogenous antiviral activity of neat 157 and dilute human saliva was measured over a contact time of 5 minutes ( Figure 3A ) during which no 158 significant reduction in viral load was observed compared to the water control. Viral titres of 5.70log10 159 PFU/mL, 5.61log10 PFU/mL and 5.45log10 PFU/mL were recovered from the neat saliva, dilute saliva 160 incubation and the water control, respectively. It is essential that mouthwashes maintain efficacy in 161 the presence of human saliva. To investigate this, we examined if the antiviral efficacy of MW-B was 162 altered by saliva. We found that MW-B was still capable of inactivation of SARS-CoV-2 to below the 163 LOD in the presence of saliva, indicating that CPC retained efficacy despite the soil load. 164 165 Figure 3 . Irradiated human saliva has no effect upon the viral titre of SARS-CoV-2 as compared to the 166 water control after incubation with inoculum for 5 minutes. Neat saliva had a ratio of 8 parts water to 167 1-part irradiated human saliva to 1-part virus inoculum, while dilute saliva had a ratio 9 parts irradiated 168 human saliva to 1-part virus inoculum ( In conclusion, two mouthwashes containing 0.07% CPC were effective at inactivating SARS-CoV-2, 203 within 30 seconds with greater than 4.0log10 PFU/ml reduction in viral titre. Moreover, virucidal 204 activity of CPC was maintained in the presence of whole human saliva. Both 0.07% CPC mouthwashes 205 were as effective as 70% ethanol against three variants of concern; Alpha, Beta and Gamma suggesting 206 

Consistent Detection of 2019 Novel 245 Coronavirus in Saliva. Clinical infectious diseases : an official publication of the Infectious Diseases 246 Society of America

SARS-CoV-2 infection of the 249 oral cavity and saliva

The COVID-19 Pathway: A Proposed 251

Oral-Vascular-Pulmonary Route of SARS-CoV-2 Infection and the Importance of Oral Healthcare 252

Brief Report: The Virucidal 254 Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro

Salivary SARS-CoV-2 257 load reduction with mouthwash use: A randomized pilot clinical trial

Antimicrobial 260 mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed 261 COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them

The Cochrane database of systematic reviews

Antiseptics and disinfectants: activity, action, and resistance. 265 Clinical microbiology reviews

Cationic antiseptics: diversity of action under a common epithet

Lytic agents, cell permeability, and monolayer penetrability. The Journal of 271 general physiology

Cetylpyridinium chloride mouth rinses 274 alleviate experimental gingivitis by inhibiting dental plaque maturation. International journal of oral 275 science

Efficacy of a high bioavailable cetylpyridinium 278 chloride mouthrinse over a 24-hour period: a plaque imaging study

Delivery of antiplaque agents from dentifrices, gels, and 281 mouthwashes

Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection. Function

Repurposing Quaternary Ammonium Compounds 288 as Potential Treatments for COVID-19

Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro

Antiseptic Mouth Rinses on SARS-CoV-2 Infectivity In Vitro. Pathogens

Inactivation of SARS-CoV-2 through 302 Treatment with the Mouth Rinsing Solutions ViruProX(®) and BacterX(®) Pro. Microorganisms

Virucidal activity of oral care products 306 against SARS-CoV-2 in vitro

Virucidal Efficacy 310 of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2

Quantitative and qualitative analyses of human salivary NEFA 314 with gas-chromatography and mass spectrometry

Organic anion composition of human whole 317 saliva as determined by ion chromatography. Clinica chimica acta; international journal of clinical 318 chemistry

Comparative bioavailability and antimicrobial activity of cetylpyridinium chloride mouthrinses in 322 vitro and in vivo

Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States

Standard Practice to Assess the Activity of Microbicides 329 against Viruses in Suspension

Efficacy of commercial 331 mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized Control Trial in Singapore

SARS-CoV-2 334 variants, spike mutations and immune escape

SARS-CoV-2 Variants of 337 Interest and Concern naming scheme conducive for global discourse